The state of Kentucky currently has 221 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Louisville, Lexington, Owensboro and Paducah.
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647
Recruiting
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2022
Locations: Flaget Memorial Hospital, Bardstown, Kentucky +9 locations
Conditions: Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Kentucky Medical Center, Lexington, Kentucky
Conditions: Breast Cancer
Register for Updates
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
NCT00682032
Recruiting
The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: James Graham Brown Cancer Center, Louisville, Kentucky
Conditions: Non Small Cell Lung Cancer
Register for Updates
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT05037825
Recruiting
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Baptist Health Clinical Research, Elizabethtown, Kentucky
Conditions: Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Register for Updates
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT04990921
Recruiting
This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/05/2021
Locations: James Graham Brown Cancer Center, Louisville, Kentucky
Conditions: Metastatic Breast Cancer
Register for Updates